As of 2026-03-20, the EV/EBITDA ratio of Oramed Pharmaceuticals Inc (ORMP) is -7.12. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ORMP's latest enterprise value is 91.50 mil USD. ORMP's TTM EBITDA according to its financial statements is -12.85 mil USD. Dividing these 2 quantities gives us the above ORMP EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2026-03-19 | -7.12 |
| 2026-03-18 | -7.00 |
| 2026-03-17 | -7.12 |
| 2026-03-16 | -6.78 |
| 2026-03-13 | -6.57 |
| 2026-03-12 | -6.41 |
| 2026-03-11 | -6.47 |
| 2026-03-10 | -6.26 |
| 2026-03-09 | -6.04 |
| 2026-03-06 | -6.12 |
| 2026-03-05 | -6.50 |
| 2026-03-04 | -7.15 |
| 2026-03-03 | -6.41 |
| 2026-03-02 | -6.29 |
| 2026-02-27 | -6.52 |
| 2026-02-26 | -6.57 |
| 2026-02-25 | -7.50 |
| 2026-02-24 | -6.66 |
| 2026-02-23 | -6.19 |
| 2026-02-20 | -5.91 |
| 2026-02-19 | -5.76 |
| 2026-02-18 | -6.16 |
| 2026-02-17 | -5.85 |
| 2026-02-13 | -6.01 |
| 2026-02-12 | -5.76 |
| 2026-02-11 | -6.01 |
| 2026-02-10 | -6.41 |
| 2026-02-09 | -6.57 |
| 2026-02-06 | -6.50 |
| 2026-02-05 | -5.98 |
| 2026-02-04 | -6.53 |
| 2026-02-03 | -6.50 |
| 2026-02-02 | -6.47 |
| 2026-01-30 | -6.38 |
| 2026-01-29 | -6.53 |
| 2026-01-28 | -6.69 |
| 2026-01-27 | -6.72 |
| 2026-01-26 | -7.06 |
| 2026-01-23 | -6.44 |
| 2026-01-22 | -6.22 |
| 2026-01-21 | -6.60 |
| 2026-01-20 | -6.84 |
| 2026-01-16 | -7.34 |
| 2026-01-15 | -7.37 |
| 2026-01-14 | -7.22 |
| 2026-01-13 | -6.44 |
| 2026-01-12 | -6.57 |
| 2026-01-09 | -6.57 |
| 2026-01-08 | -6.72 |
| 2026-01-07 | -6.07 |